Skip to main content
SpringerLink
Log in
Book cover

Ocular Transporters In Ophthalmic Diseases And Drug Delivery pp 235–253Cite as

P-Glycoprotein Expression and Function in the Retinal Pigment Epithelium

  • Chapter

Part of the book series: Ophthalmology Research ((OPHRES))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. 1. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85:845–881.

    Article  PubMed  CAS  Google Scholar 

  2. 2. Miyamoto Y, Kulanthaivel P, Leibach FH, Ganapathy V. Taurine uptake in apical membrane vesicles from the bovine retinal pigment epithelium. Invest Ophthalmol Vis Sci 1991;32:2542–2551.

    PubMed  CAS  Google Scholar 

  3. 3. Philp NJ, Wang D, Yoon H, Hjelmeland LM. Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells. Invest Ophthalmol Vis Sci 2003;44:1716–1721.

    Article  PubMed  Google Scholar 

  4. 4. Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. Invest Ophthalmol Vis Sci 1994;35:2887–2894.

    PubMed  CAS  Google Scholar 

  5. 5. Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel J-M, Sirotnak FM, Roon P, Ganapathy V, Smith SB. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 2000;275:20676–20684.

    Article  PubMed  CAS  Google Scholar 

  6. 6. Han YH, Sweet DH, Hu DN, Pritchard JB. Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells. J Pharmacol Exp Ther 2001;296:450–457.

    PubMed  CAS  Google Scholar 

  7. 7. Gao B, Wenzel A, Grimm C, Vavricka SR, Benke D, Meier PJ, Reme CE. Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 2002;43:510–514.

    PubMed  Google Scholar 

  8. 8. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, Stoll D, Schlosshauer B. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci 2005;46:1047–1053.

    Article  PubMed  Google Scholar 

  9. 9. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006;58:1136–1163.

    Article  PubMed  CAS  Google Scholar 

  10. 10. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316:817–819.

    Article  PubMed  CAS  Google Scholar 

  11. 11. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989;9:3808–3820.

    PubMed  CAS  Google Scholar 

  12. 12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proced Natl Acad Sci USA 1987;84:265–269.

    Article  CAS  Google Scholar 

  13. 13. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–7738.

    Article  PubMed  CAS  Google Scholar 

  14. 14. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 1997;49:80–88.

    Article  PubMed  CAS  Google Scholar 

  15. 15. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF. Structural model of ATP-binding protein associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362–365.

    Article  PubMed  CAS  Google Scholar 

  16. 16. Stefkova J, Poledne R, Hubacek JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Rev 2004;53:235–243.

    CAS  Google Scholar 

  17. 17. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987;77:142–144.

    Article  PubMed  CAS  Google Scholar 

  18. 18. Loo TW, Bartlett MC, Clarke DM. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. Biochemistry 2005;44:10250–10258.

    Article  PubMed  CAS  Google Scholar 

  19. 19. Loo TW and Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 1999;13:1724–1732.

    PubMed  CAS  Google Scholar 

  20. 20. Azzaria M, Schurr E, Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 1989;9:5289–5297.

    PubMed  CAS  Google Scholar 

  21. 21. Chen C-j, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381–389.

    Article  PubMed  CAS  Google Scholar 

  22. 22. Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 1990;265: 7679–7686.

    PubMed  CAS  Google Scholar 

  23. 23. Hamada H, Hagiwara K, Nakajima T, Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 1987;47:2860–2865.

    PubMed  CAS  Google Scholar 

  24. 24. Chambers TC, Pohl J, Glass DB, Kuo JF. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J 1994;299:309–315.

    PubMed  CAS  Google Scholar 

  25. 25. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006;8:143–152.

    Article  PubMed  CAS  Google Scholar 

  26. 26. Kim IW, Peng XH, Sauna ZE, FitzGerald PC, Xia D, Muller M, Nandigama K, Ambudkar SV. The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: Evidence for a conserved subdomain, the A-loop in the ATP-Binding Cassette. Biochemistry 2006;45:7605–7616.

    Article  PubMed  CAS  Google Scholar 

  27. 27. Loo TW and Clarke DM. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates. Biochemistry 1999;38:5124–5129.

    Article  PubMed  CAS  Google Scholar 

  28. 28. Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele Jr G, Summerhayes IC. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995;71:670–675.

    Article  PubMed  CAS  Google Scholar 

  29. 29. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 2001;20:5615–5625.

    Article  PubMed  CAS  Google Scholar 

  30. 30. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance p-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003;278:8294–8299.

    Article  PubMed  CAS  Google Scholar 

  31. 31. Ramakrishnan P. The role of P-glycoprotein in the blood-brain barrier. Einstein Quart. J Biol Med 2003;19:160–165.

    CAS  Google Scholar 

  32. 32. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. In Situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006;54:1159–1167.

    Article  PubMed  CAS  Google Scholar 

  33. 33. Del Moral RG, Olmo A, Aguilar M, O'Valle F. P glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Exp Nephrol 1998;6:89–97.

    Article  PubMed  Google Scholar 

  34. 34. Gottesman MM and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385–427.

    Article  PubMed  CAS  Google Scholar 

  35. 35. Pleban K, Kopp S, Csaszar E, Peer M, Hrebicek T, Rizzi A, Ecker GF, Chiba P. P-Glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol 2005;67:365–374.

    Article  PubMed  CAS  Google Scholar 

  36. 36. Loo TW, Bartlett MC, Clarke DM. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biophys J 2006;399:351–359.

    CAS  Google Scholar 

  37. 37. Loo TW, Bartlett MC, Clarke DM. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biophys J 2006;396:537–545.

    CAS  Google Scholar 

  38. 38. Juliano RL and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica Biophysica Acta 1976;455:152–162.

    Article  CAS  Google Scholar 

  39. 39. Riordan JR and Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979;254:12701–12705.

    PubMed  CAS  Google Scholar 

  40. 40. Kartner N, Shales M, Riordan JR, Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 1983;43:4413–4419.

    PubMed  CAS  Google Scholar 

  41. 41. Chan HS, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SP, Deeley RG, Ling V, Gallie BL. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 1997;57:2325–2330.

    PubMed  CAS  Google Scholar 

  42. 42. Wilson MW, Fraga CH, Fuller CE, Rodriguez-Galindo C, Mancini J, Hagedorn N, Leggas ML, Stewart CF. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 2006;47:1269–1273.

    Article  PubMed  Google Scholar 

  43. 43. Mc Namara M, Clynes M, Dunne B, NicAmhlaoibh R, Lee WR, Barnes C, Kennedy SM. Multidrug resistance in ocular melanoma. Br J Ophthalmol 1996;80:1009–1112.

    Article  Google Scholar 

  44. 44. Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of P-glycoprotein in multidrug resistant cells with photoactive analogs of colchicine. Biochem Biophys Res Commun 1989;162:1402–1408.

    Article  PubMed  CAS  Google Scholar 

  45. 45. Roos E and Van de Pavert IV. Effect of tubulin-binding agents on the infiltration of tumour cells into primary hepatocyte cultures. J Cell Sci 1982;55:233–245.

    PubMed  CAS  Google Scholar 

  46. 46. Chaplin DJ and Horsman MR. Tumor blood flow changes induced by chemical modifiers of radiation response. Int J Radiat Oncol Biol Phys 1992;22:459–462.

    Article  PubMed  CAS  Google Scholar 

  47. 47. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859–1876.

    Article  PubMed  CAS  Google Scholar 

  48. 48. Fardel O, Lecureur V, Corlu A, Guillouzo A. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. Biochem Pharmacol 1996;51:1427–1436.

    Article  PubMed  CAS  Google Scholar 

  49. 49. Ferry DR, Russell MA, Cullen MH. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site. Biochem Biophys Res Commun 1992;188:440–445.

    Article  PubMed  CAS  Google Scholar 

  50. 50. de Lannoy IAM and Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551–557.

    Article  PubMed  Google Scholar 

  51. 51. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289–294.

    Article  PubMed  CAS  Google Scholar 

  52. 52. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248–24252.

    PubMed  CAS  Google Scholar 

  53. 53. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993;67:284–289.

    Article  PubMed  Google Scholar 

  54. 54. Tsuji A, Tamai I, Sakata A, Tenda Y and Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993;46:1096–1099.

    Article  PubMed  CAS  Google Scholar 

  55. 55. Safa AR, Agresti M, Tamai I, Mehta ND, Vahabi S. The alpha 1-adrenergic photoaffinity probe [125I]arylazidoprazosin binds to a specific peptide of P-glycoprotein in multidrug-resistant cells. Biochem Biophys Res Commun 1990;166:259–266.

    Article  PubMed  CAS  Google Scholar 

  56. 56. Schuetz EG, Yasuda K, Arimori K, Schuetz JD. Human MDR and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 1998;350:340–347.

    Article  PubMed  CAS  Google Scholar 

  57. 57. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289–294.

    Article  PubMed  CAS  Google Scholar 

  58. 58. Loe DW and Sharom FJ. Interaction of multidrug-resistant Chinese hamster ovary cells with the peptide ionophore gramicidin D. Biochim Biophys Acta 1994;1190:72–84.

    Article  PubMed  CAS  Google Scholar 

  59. 59. Goda K, Krasznai Z, Gaspar R, Lankelma J, Westerhoff HV, Damjanovich S, Szabo J, Gabor. Reversal of multidrug resistance by valinomycin is overcome by CCCP. Biochem Biophys Res Commun 1996;219:306–310.

    Article  PubMed  CAS  Google Scholar 

  60. 60. Huwyler J, Drewe J, Klusemann C; Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 1996;118:1879–1885.

    PubMed  CAS  Google Scholar 

  61. 61. Efferth T, Lohrke H, Volm M. Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 1989;9:1633–1637.

    PubMed  CAS  Google Scholar 

  62. 62. Homolya L, Hollo Z, Germann U, Pastan I, Gottesman M, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493–21496.

    PubMed  CAS  Google Scholar 

  63. 63. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594–3601.

    Article  PubMed  CAS  Google Scholar 

  64. 64. Callaghan R and Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug- resistant cells. J Biol Chem 1993;268:16059–16064.

    PubMed  CAS  Google Scholar 

  65. 65. Henthorn TK, Liu Y, Mahapatro M, Ng K-Y. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 1999;289:1084–1089.

    PubMed  CAS  Google Scholar 

  66. 66. Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 1993;110:1009–1016.

    PubMed  CAS  Google Scholar 

  67. 67. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-Length cDNA for the Human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987;84:3004–3008.

    Article  PubMed  CAS  Google Scholar 

  68. 68. Janice H, Barry HH, Nicholas LS. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial CACO-2 cell layers. Pharm Res 1993;10:743–749.

    Article  Google Scholar 

  69. 69. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.

    PubMed  CAS  Google Scholar 

  70. 70. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263:840–845.

    PubMed  CAS  Google Scholar 

  71. 71. Sanna T-S, Jarkko R, Steve W, Joseph WP, James EP. Midazolam exhibits characteristics of a highly permeable p-glycoprotein substrate. Pharma Res 2003;20:757–764.

    Article  Google Scholar 

  72. 72. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line CACO-2. J Pharmacol Exp Ther 1999;288:171–178.

    PubMed  CAS  Google Scholar 

  73. 73. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 1987;84:9261–9264.

    Article  PubMed  CAS  Google Scholar 

  74. 74. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491–502.

    Article  PubMed  CAS  Google Scholar 

  75. 75. Gutmann H, Miller DS, Droulle A, Drewe J, Fahr A, Fricker G. P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol 2000;129:251–256.

    Article  PubMed  CAS  Google Scholar 

  76. 76. Hollo Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1994;1191:384–388.

    Article  PubMed  CAS  Google Scholar 

  77. 77. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353–363.

    PubMed  CAS  Google Scholar 

  78. 78. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1–6.

    Article  PubMed  CAS  Google Scholar 

  79. 79. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphona 2000;38:1–11.

    CAS  Google Scholar 

  80. 80. Romsicki Y and Sharom FJ. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 2001;40:6937–6947.

    Article  PubMed  CAS  Google Scholar 

  81. 81. Eckford PD and Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 2005;389:517–526.

    Article  PubMed  CAS  Google Scholar 

  82. 82. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 2004;11:1028–1037.

    Article  PubMed  CAS  Google Scholar 

  83. 83. Toshiyuki S, Tsutomu N, Midori H, Takashi K, Atsushi W, Tatsurou Y, Hironao K, Shunji N, Noboru O, Takayoshi Y, Toshiro S, Akinobu G, Masafumi M, Katsuhiko O. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 2002;19:1323–1329.

    Article  Google Scholar 

  84. 84. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992;355:830–833.

    Article  PubMed  CAS  Google Scholar 

  85. 85. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992;71:23–32.

    Article  PubMed  CAS  Google Scholar 

  86. 86. Luker GD, Nilsson KR, Covey DF, Piwnica-Worms D. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 1999;274:6979–6991.

    Article  PubMed  CAS  Google Scholar 

  87. 87. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 2006;6:295–311.

    Article  PubMed  CAS  Google Scholar 

  88. 88. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006;26:1601–1607.

    Article  PubMed  CAS  Google Scholar 

  89. 89. Er-Jia W, Christopher NC, Robert PC, William WJ. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharmaceutical Res 2001;18:800–806.

    Article  Google Scholar 

  90. 90. Cornwell M, Pastan I, Gottesman M. Certain calcium channel blockers bind specifically to multidrug- resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166–2170.

    PubMed  CAS  Google Scholar 

  91. 91. Pötschka H, Fedrowitz M, Löscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbemazepine in the brain. Neuroreport 2001;12:3557–3560.

    Article  PubMed  Google Scholar 

  92. 92. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of side-effects of modern antihistamines. J Drug Target 2001;9:223–228.

    Article  PubMed  CAS  Google Scholar 

  93. 93. Hämmerle SP, Rothen-Rutishauser B, Krämer SD, Günthert M, Wunderli-Allenspach H. P-glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur J Pharm Sci 2000;12:69–77.

    Article  PubMed  Google Scholar 

  94. 94. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003;990:95–112.

    Article  PubMed  CAS  Google Scholar 

  95. 95. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun. 1988;153:959–966.

    Article  PubMed  CAS  Google Scholar 

  96. 96. Garrigos M, Belehradek J, Mir LM, Orlowski S. Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Biochem Biophys Res Commun 1993;196:1034–1041.

    Article  PubMed  CAS  Google Scholar 

  97. 97. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci US A 1988;85:3580–3585.

    Article  CAS  Google Scholar 

  98. 98. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652–1660.

    PubMed  CAS  Google Scholar 

  99. 99. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861–879.

    Article  PubMed  CAS  Google Scholar 

  100. 100. Thomas H and Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159–165.

    PubMed  Google Scholar 

  101. 101. Randall PR, Albert E, Richard L, Tomasz MB, Yoo-Joung K, Henner WD, Glenn B, Elizabeth AM, Varun G, Ene E, Matthew WH, William SD. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Can Chemo Pharmacol 2003;51:297–305.

    Google Scholar 

  102. 102. Van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FALM, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002;38:1090–1099.

    Article  PubMed  Google Scholar 

  103. 103. Kennedy BG and Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis 2002;8:422–430.

    PubMed  CAS  Google Scholar 

  104. 104. Sharom FJ, Yu X, Lu P, Liu R, Chu JWK, Szabo K, Muller M, Hose CD, Monks A, Varadi A. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochemical Pharmacology 1999;58:571–586.

    Article  PubMed  CAS  Google Scholar 

  105. 105. Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int J Cancer 2006;119:414–422.

    Article  PubMed  CAS  Google Scholar 

  106. 106. Wesolowska O, Molnar J, Westman G, Samuelsson K, Kawase M, Ocsovszki I, Motohashi N, Michalak K. Benzo[a]phenoxazines: a new group of potent P-glycoprotein inhibitors. In Vivo 2006;20:109–113.

    PubMed  CAS  Google Scholar 

  107. 107. Koubeissi A, Raad I, Ettouati L, Guilet D, Dumontet C, Paris J. Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. Bioorganic Med Chem Letts 2006;16:5700–5703.

    Article  CAS  Google Scholar 

  108. 108. Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 2007;17:117–122.

    PubMed  CAS  Google Scholar 

  109. 109. Rittierodt M, Tschernig T, Harada K. Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 2004;71:123–128.

    Article  PubMed  CAS  Google Scholar 

  110. 110. Foxwell BM, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989;36:543–546.

    PubMed  CAS  Google Scholar 

  111. 111. Pourtier-Manzanedo A, Boesch D, Loor F. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. Anticancer Drugs 1991;2:279–283.

    Article  PubMed  CAS  Google Scholar 

  112. 112. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992;80:1528–1536.

    PubMed  CAS  Google Scholar 

  113. 113. Wang E-J, Casciano CN, Clement RP, Johnson WW. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001;61:7525–7529.

    PubMed  CAS  Google Scholar 

  114. 114. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987;262:7884–7888.

    PubMed  CAS  Google Scholar 

  115. 115. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 1999;58:1801–1806.

    Article  PubMed  CAS  Google Scholar 

  116. 116. Hofsli E and Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 1989;44:149–154.

    Article  PubMed  CAS  Google Scholar 

  117. 117. Fardel O, Lecureur V, Loyer P, Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 1995;49:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  118. 118. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J, Ocsovszky I, Molnar J. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 1996;16:209–211.

    PubMed  CAS  Google Scholar 

  119. 119. Esser P, Tervooren D, Heimann K, Kociok N, Bartz-Schmidt KU, Walter P, Weller M. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:164–170.

    PubMed  CAS  Google Scholar 

  120. 120. Luo Y, Zhuo Y, Fukuhara M, Rizzolo LJ. Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest Ophthalmol Vis Sci 2006;47:3644–3655.

    Article  PubMed  Google Scholar 

  121. 121. Tian J, Ishibashi K, Handa JT. The expression of native and cultured RPE grown on different matrices. Physiol Genomics 2004;17:170–182.

    Article  PubMed  CAS  Google Scholar 

  122. 122. Hu J and Bok D. A cell culture medium that supports the differentiation of human retinal pigment epithelium into functionally polarized monolayers. Mol Vis 2001;7:14–19.

    PubMed  CAS  Google Scholar 

  123. 123. Peng S, Rahner C, Rizzolo LJ. Apical and basal regulation of the permeability of the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003;44:808–817.

    Article  PubMed  Google Scholar 

  124. 124. Constable PA, Lawrenson JG, Dolman DEM, Arden GB, Abbott NJ. P-Glycoprotein expression in retinal pigment epithelium cell lines. Exp Eye Res 2006;83:24–30.

    Article  PubMed  CAS  Google Scholar 

  125. 125. Greenwood J. Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. J Neuroimmunol 1992;39: 123–132.

    Article  PubMed  CAS  Google Scholar 

  126. 126. Wang L, Chen L, Walker V, Jacob TJC. Antisense to MDR1 mRNA reduces P-glycoprotein expression, swelling-activated Cl- current and volume regulation in bovine ciliary epithelial cells. J Physiol 1998;511:33–44.

    Article  PubMed  CAS  Google Scholar 

  127. 127. Chen LX, Wang LW, Jacob T. The role of MDR1 gene in volume-activated chloride currents in pigmented ciliary epithelial cells. Acta Physiol Sinca 2002;54:1–6.

    CAS  Google Scholar 

  128. 128. Harding GF, Wild JM, Robertson KA, Lawden MC, Betts TA, Barber C, Barnes PM. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000;41:1420–1431.

    Article  PubMed  CAS  Google Scholar 

  129. 129. Weiss J, Kerpen CJ, Lindenmaier H, Dormann S-M G, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003;307:262–267.

    Article  PubMed  CAS  Google Scholar 

  130. 130. Crowe A and Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target 2006;14:291–300.

    Article  PubMed  CAS  Google Scholar 

  131. 131. Lawrenson JG, Kelly C, Lawrenson AL, Birch J. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol 2002;86:1259–1261.

    Article  PubMed  CAS  Google Scholar 

  132. 132. Castells DD, Teitelbaum BA, Tresley DJ. Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. Optometry 2002;73:113–121.

    PubMed  Google Scholar 

  133. 133. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceed Natl Acad Sci U S A 1997;94:4028–4033.

    Article  CAS  Google Scholar 

  134. 134. Flage T. A defect in the blood-retina barrier in the optic nerve head region in the rabbit and the monkey. Acta Ophthalmol (Copenh) 1980;58:645–651.

    Article  CAS  Google Scholar 

  135. 135. Cohen AI. Is there a potential defect in the blood-retinal barrier at the choroidal level of the optic nerve canal? Invest Ophthalmol Vis Sci 1973;12:513–519.

    CAS  Google Scholar 

  136. 136. Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BenEzra D, Behar-Cohen F. Ocular gene therapy: a review of nonviral strategies. Mol Vis 2006;12:1334–1347.

    PubMed  CAS  Google Scholar 

  137. 137. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004;45:238–244.

    Article  PubMed  Google Scholar 

  138. 138. Amaral J, Fariss RN, Campos MM, Robison Jr WG, Kim H, Lutz R, Becerra SP. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest Ophthalmol Vis Sci 2005;46:4383–4392.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Optometry and Visual Science, City University, Henry Wellcome Laboratories for Visual Sciences, City University, London, UK

    Paul A. Constable & John G. Lawrenson

  2. Pharmaceutical Science Research Division, School of Biomedical and Health Sciences, King's College, London, UK

    N. Joan Abbott

Authors
  1. Paul A. Constable
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John G. Lawrenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Joan Abbott
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, USA

    Joyce Tombran-Tink Phd  & Joyce Tombran-Tink Phd  & 

  2. Department of Neural andBehavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA

    Colin J. Barnstable Dphil  & Colin J. Barnstable Dphil  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science + Business Media, LLC

About this chapter

Cite this chapter

Constable, P.A., Lawrenson, J.G., Abbott, N.J. (2008). P-Glycoprotein Expression and Function in the Retinal Pigment Epithelium. In: Tombran-Tink, J., Barnstable, C.J. (eds) Ocular Transporters In Ophthalmic Diseases And Drug Delivery. Ophthalmology Research. Humana Press. https://doi.org/10.1007/978-1-59745-375-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-375-2_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-958-1

  • Online ISBN: 978-1-59745-375-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation